---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-011120"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2022-04-28T23:59:59+00:00"
generated_at: "2026-06-26T03:19:42.371053+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Esperion appoints Stephen Rocamboli to board; Dr. Mark McGovern resigns

## Summary
- Mark McGovern resigned from board effective April 28, 2022; no disagreement cited.
- Stephen Rocamboli elected to fill vacancy; will serve on Audit Committee.
- Rocamboli is CEO of Perla Therapeutics, with prior life science board and executive roles.
- Esperion expects topline readout of CLEAR Outcomes trial in Q1 2023.

## SEC filing metadata
- accession: 0001628280-22-011120
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2022-04-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828022011120/0001628280-22-011120-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828022011120/espr-20220428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-011120
- JSON: https://secwatch.observer/filing/0001628280-22-011120.json
- Plain text: https://secwatch.observer/filing/0001628280-22-011120.txt

## Key facts
- Executive change
  Mark E. McGovern resigned as Director at Esperion Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On April 28, 2022, Mark E. McGovern, M.D. notified the Board of Directors (the “Board”) of Esperion Therapeutics, Inc (the “Company”) of his decision to resign from the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828022011120/0001628280-22-011120-index.htm
- Executive change
  Stephen Rocamboli was elected as Director at Esperion Therapeutics, Inc..
  - Action: elected
  - Role: Director
  source text: On April 28, 2022, the Board elected Stephen Rocamboli to fill the newly created vacancy on the Board resulting from Dr. McGovern’s resignation from the Board, effective April 28, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828022011120/0001628280-22-011120-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.